Melanoma is a lethal form of skin cancer because it has a high propensity to metastasize, especially to the brain (often causing death). Compounding this problem is the obs...

Melanoma brain metastases (MBM) are a leading cause of morbidity and mortality for patients with advanced disease. Modern systemic therapies do not adequately control brain...

While significant progress has been made in developing new therapeutics to control melanoma, the promising clinical outcomes of immune checkpoint inhibitors have drasticall...

Adoptive cell therapy (ACT) using naturally occurring tumor-infiltrating lymphocytes (TIL) can mediate durable tumor regressions and, in some cases, cure in patients with m...

About 40% of melanoma patients have decreased p16, a tumor suppressor protein that inhibits cell proliferation. However, our laboratory and others have found that p16 can r...

Despite recent therapeutic advances, melanoma remains a major burden that is expected to rise faster than any other cancer in the coming decades. Surgery is frequently cura...

Gender is an important factor in patients with melanoma. Female melanoma patients have an advantage over their male counterparts in terms of survival. However, the reason f...

In the U.S. alone during 2021, an estimated 106,110 and 101,280 people will be diagnosed with invasive and non-invasive (in situ) melanoma, respectively. Moreover, it is ex...

The major reason melanoma causes illness and death in patients is because the melanoma cells from the skin can travel to lymph nodes or into the blood which allows them to ...

Therapies that inhibit epigenetic modulators can induce a state of “virus mimicry” in cancer cells by activating long-overlooked “junk DNA” of the human genome. Thi...